Cantor Fitzgerald Predicts ARWR FY2025 Earnings

Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) – Stock analysts at Cantor Fitzgerald issued their FY2025 earnings per share estimates for Arrowhead Pharmaceuticals in a research note issued on Tuesday, January 21st. Cantor Fitzgerald analyst P. Agrawal expects that the biotechnology company will post earnings of ($4.20) per share for the year. The consensus estimate for Arrowhead Pharmaceuticals’ current full-year earnings is ($3.30) per share.

A number of other analysts have also recently commented on ARWR. Royal Bank of Canada restated an “outperform” rating and issued a $42.00 price objective on shares of Arrowhead Pharmaceuticals in a research report on Thursday, September 26th. Piper Sandler cut their target price on shares of Arrowhead Pharmaceuticals from $62.00 to $45.00 and set an “overweight” rating for the company in a research note on Wednesday, November 27th. HC Wainwright reaffirmed a “buy” rating and issued a $80.00 price target on shares of Arrowhead Pharmaceuticals in a research note on Friday, December 20th. Chardan Capital reiterated a “buy” rating and set a $60.00 price objective on shares of Arrowhead Pharmaceuticals in a research note on Thursday, December 12th. Finally, Citigroup lowered their price target on Arrowhead Pharmaceuticals from $27.00 to $26.00 and set a “neutral” rating on the stock in a research note on Wednesday, November 27th. One investment analyst has rated the stock with a sell rating, four have issued a hold rating and six have given a buy rating to the stock. According to data from MarketBeat, Arrowhead Pharmaceuticals has an average rating of “Hold” and a consensus target price of $43.33.

Arrowhead Pharmaceuticals Stock Up 1.0 %

ARWR stock opened at $19.76 on Wednesday. Arrowhead Pharmaceuticals has a 52-week low of $17.05 and a 52-week high of $36.72. The company has a debt-to-equity ratio of 2.06, a current ratio of 6.74 and a quick ratio of 6.74. The company’s 50-day simple moving average is $20.73 and its 200-day simple moving average is $22.09.

Insiders Place Their Bets

In related news, Director William D. Waddill sold 3,748 shares of the stock in a transaction that occurred on Monday, December 16th. The shares were sold at an average price of $21.90, for a total transaction of $82,081.20. Following the completion of the transaction, the director now owns 44,125 shares of the company’s stock, valued at approximately $966,337.50. This trade represents a 7.83 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, CEO Christopher Richard Anzalone sold 11,520 shares of the business’s stock in a transaction that occurred on Thursday, January 2nd. The shares were sold at an average price of $19.05, for a total value of $219,456.00. Following the completion of the sale, the chief executive officer now directly owns 3,764,252 shares in the company, valued at approximately $71,709,000.60. The trade was a 0.31 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 146,473 shares of company stock valued at $2,937,847 over the last ninety days. Company insiders own 4.50% of the company’s stock.

Institutional Investors Weigh In On Arrowhead Pharmaceuticals

Several large investors have recently added to or reduced their stakes in the business. HighTower Advisors LLC lifted its stake in Arrowhead Pharmaceuticals by 11.5% in the third quarter. HighTower Advisors LLC now owns 123,477 shares of the biotechnology company’s stock worth $2,401,000 after acquiring an additional 12,706 shares during the last quarter. Intech Investment Management LLC purchased a new stake in shares of Arrowhead Pharmaceuticals during the 3rd quarter worth $659,000. Erste Asset Management GmbH acquired a new position in shares of Arrowhead Pharmaceuticals during the third quarter worth $924,000. Millennium Management LLC increased its holdings in Arrowhead Pharmaceuticals by 61.9% in the second quarter. Millennium Management LLC now owns 529,251 shares of the biotechnology company’s stock valued at $13,755,000 after buying an additional 202,280 shares during the last quarter. Finally, Geode Capital Management LLC lifted its holdings in Arrowhead Pharmaceuticals by 0.9% during the 3rd quarter. Geode Capital Management LLC now owns 2,964,119 shares of the biotechnology company’s stock worth $57,426,000 after buying an additional 26,171 shares during the last quarter. 62.61% of the stock is owned by hedge funds and other institutional investors.

About Arrowhead Pharmaceuticals

Arrowhead Pharmaceuticals, Inc develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes Plozasiran, which is in Phase 2b and one Phase 3 clinical trial to treat hypertriglyceridemia, mixed dyslipidemia, and chylomicronemia syndrome; Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with non-alcoholic steatohepatitis; ARO-RAGE that is in Phase 1/2a clinical trial to treat inflammatory pulmonary conditions; and ARO-MUC5AC, which is in Phase 1/2a clinical trial to treat muco-obstructive pulmonary diseases.